KRAS and colorectal carcinoma: A subset of poor-prognosis BRAF-mutant-like (BRAFm) patients, defined as having tumors with gene expression profiles similar to known BRAFm tumors, were previously identified in a KRAS wt CRC cohort using a predictor based on differential expression of 32 gene pairs [17].